Ding Shanshan, Dong Xiaohan, Song Xingguo
Department of Clinical Laboratory, Shandong Cancer Hospital & Institute, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, PR China.
Department of Laboratory Medicine, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
Cancer Cell Int. 2023 May 11;23(1):91. doi: 10.1186/s12935-023-02927-5.
Platelets, involved in the whole process of tumorigenesis and development, constantly absorb and enrich tumor-specific substances in the circulation during their life span, thus called "Tumor Educated Platelets" (TEPs). The alterations of platelet mRNA profiles have been identified as tumor markers due to the regulatory mechanism of post-transcriptional splicing. Small nuclear RNAs (SnRNAs), the important spliceosome components in platelets, dominate platelet RNA splicing and regulate the splicing intensity of pre-mRNA. Endogenous variation at the snRNA levels leads to widespread differences in alternative splicing, thereby driving the development and progression of neoplastic diseases. This review systematically expounds the bidirectional tumor-platelets interactions, especially the tumor induced alternative splicing in TEP, and further explores whether molecules related to alternative splicing such as snRNAs can serve as novel biomarkers for cancer diagnostics.
血小板参与肿瘤发生和发展的全过程,在其生命周期中不断吸收并富集循环中的肿瘤特异性物质,因此被称为“肿瘤驯化血小板”(TEPs)。由于转录后剪接的调控机制,血小板mRNA谱的改变已被确定为肿瘤标志物。小核RNA(SnRNAs)是血小板中重要的剪接体成分,主导血小板RNA剪接并调节前体mRNA的剪接强度。SnRNA水平的内源性变化导致可变剪接的广泛差异,从而推动肿瘤性疾病的发生和发展。本文综述系统阐述了肿瘤与血小板的双向相互作用,特别是肿瘤诱导的TEP中的可变剪接,并进一步探讨了与可变剪接相关的分子如SnRNAs是否可作为癌症诊断的新型生物标志物。